New Cancer Immunotherapy Target Identified by Australian Research
Unlocking Cancer‘s Secrets: New Research Could Supercharge Immunotherapy
Scientists have made a groundbreaking discovery that could significantly enhance the effectiveness of immunotherapy for certain cancers.
Immunotherapy, a revolutionary treatment that harnesses the body’s own immune system to fight cancer, has shown remarkable promise in recent years. However, certain molecules can act as brakes, limiting the ability of T cells – the immune system’s warriors – to target and destroy cancer cells.
Now, Australian researchers have cracked the code on one of these molecular brakes: LAG-3. Their findings, published in the prestigious journal Science Immunology, reveal the precise structure of how LAG-3 interacts with its main target, a molecule called HLA-II.
“The way other immune checkpoint molecules, like PD-1 and CTLA-4, bind to their targets has been known for years,” explains Professor Jamie Rossjohn, lead researcher from Monash University’s biomedicine Discovery Institute.”But the LAG-3 interaction remained a mystery until now.”
This breakthrough, achieved using data from the Australian synchrotron, provides a crucial blueprint for developing new therapies that can block LAG-3 and unleash the full potential of the immune system against cancer.
“This structural information is like a key that unlocks the door to designing more effective LAG-3-blocking drugs,” says Professor Rossjohn.
The research, conducted in collaboration with Immutep, a biotechnology company focused on developing LAG-3-targeted therapies, has notable implications for cancer patients.
“These findings add to our growing understanding of LAG-3 and its role in controlling the immune response,” says Dr. Frédéric Triebel, Immutep’s Chief Scientific officer. “this knowledge will be instrumental in advancing our anti-LAG-3 small molecule program and bringing new treatment options to patients.”
The discovery of the LAG-3/HLA-II structure marks a major step forward in the fight against cancer, paving the way for more targeted and effective immunotherapies in the future.
Unlocking Cancer’s Secrets: New research Could Supercharge Immunotherapy
NewsDirectory3 Exclusive Interview
Professor jamie Rossjohn, lead researcher from monash University’s Biomedicine Revelation Institute and Dr. Frédéric Triebel, Chief Scientific Officer of Immutep, sat down with us to discuss their groundbreaking discovery regarding LAG-3, a molecule that could hold the key to unlocking more effective cancer treatments.
ND3: Professor Rossjohn, your team has made a notable breakthrough in understanding a molecule called LAG-3. Can you explain what makes this discovery so important in the fight against cancer?
Professor Rossjohn: Immunotherapy has already shown great promise in treating certain cancers, but scientists have known for some time that molecules like LAG-3 act as “brakes” on our immune system’s ability to attack cancer cells. What our research has achieved is to finally crack the code on how LAG-3 interacts with its target, a molecule called HLA-II.
ND3: Dr. Triebel, your company, Immutep, is focused on developing LAG-3-targeted therapies. How might Professor Rossjohn’s discovery impact your research and development efforts?
Dr. Triebel: This is truly a major milestone for us. Having a clear structural understanding of the LAG-3/HLA-II interaction is like having a blueprint for designing more effective drugs that can block LAG-3 and unleash the full power of the immune system against cancer.
ND3: What are the potential implications of this discovery for cancer patients?
Professor Rossjohn: This research opens the door for a new generation of immunotherapies that could be more targeted and effective than current treatments. By removing the “brakes” on the immune system, we could perhaps allow the body’s own defenses to destroy cancer cells more successfully.
ND3: what are the next steps in your research?
Dr. Triebel: immutep is now well positioned to advance our anti-LAG-3 small molecule program and bring new treatment options to patients in need. This discovery provides us with a critical piece of the puzzle that will accelerate our research and development efforts.
We are on the cusp of a new era in cancer treatment, and this discovery is a major step forward in our quest to find effective cures.